Premium
Congenital and acquired neutropenias consensus guidelines on therapy and follow‐up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica)
Author(s) -
Fioredda Francesca,
Calvillo Michaela,
Bonanomi Sonia,
Coliva Tiziana,
Tucci Fabio,
Farruggia Piero,
Pillon Marta,
Martire Baldassarre,
Ghilardi Roberta,
Ramenghi Ugo,
Renga Daniela,
Menna Giuseppe,
Pusiol Anna,
Barone Angelica,
Gambineri Eleonora,
Palazzi Giovanni,
Casazza Gabriella,
Lanciotti Marina,
Dufour Carlo
Publication year - 2012
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.22242
Subject(s) - medicine , neutropenia , pediatrics , pancytopenia , consensus conference , intensive care medicine , bone marrow , chemotherapy
The management of congenital and acquired neutropenias presents some differences according to the type of the disease. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is not standardized and scanty data are available on the best schedule to apply. The frequency and the type of longitudinal controls in patients affected with neutropenias are not usually discussed in the literature. The Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document that includes recommendations on neutropenia treatment and timing of follow-up.